Accéder au contenu
Merck

The effects of midazolam and dexmedetomidine infusion on peri-operative anxiety in regional anesthesia.

Middle East journal of anaesthesiology (2013-07-10)
Elif Senses, Alparslan Apan, Emine Arzu Köse, Gökşen Oz, Hatice Rezaki
RÉSUMÉ

This study aimed to compare the influences ofmidazolam and dexmedetomidine infusion on anxiety scores in patients undergoing surgery with regional anesthesia. Eighty ASA I or II class patient undergoing elective surgery with regional anesthesia were included in the study. Permanent anxiety scores were determined using the State-Trait Anxiety Inventory (STAI)-1 and 2 one day before the surgery. In Group I patients, dexmedetomidine 0.5 micro g/kg basal infusion for 10 min and 0.5 micro g/kg/h for maintenance was administered. In Group II patients, midazolam infusion at a rate of 0.05 mg/kg for 10 min and 0.05 mg/kg/h for maintenance was administered. The sedation scores were determined every 5 min. The steady state anxiety scores of the patients were determined one day before, 30 min after operation, at the end of the operation, and at 30 min and day 7 postoperatively using STAI-1 score. Side effects were determined and recorded. Sedation scores were comparable in both of two treatment groups. Anxiety scores were maintained with drug infusions. The incidences of side effects were significantly decreased in midazolam group compared to the dexmedetomidine group. Midazolam infusion was found to be more appropriate and efficient than dexmedetomidine during regional anesthesia practice. Dexmedetomidine infusion should be cautiously used in regional anesthetic techniques performing symphathetic blockade.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Midazolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®